First-line lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: updated results from CLEAR study

In the primary analysis of the CLEAR study (200 centers in 20 countries), first-line lenvatinib plus pembrolizumab significantly improved progression-free survival and overall survival versus sunitinib in patients with advanced renal cell carcinoma. Extended follow-up of the study showed that efficacy benefits of lenvatinib plus pembrolizumab over sunitinib were durable and clinically meaningful. The authors conclude that these results support the use of lenvatinib plus pembrolizumab as a first-line therapy for patients with advanced renal cell carcinoma.